Related references
Note: Only part of the references are listed.Uremic Toxicity of Advanced Glycation End Products in CKD
Andrea E. M. Stinghen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention
Sho-ichi Yamagishi et al.
NUTRITION (2016)
Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE
Takanori Matsui et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Linking RAGE and Nox in diabetic micro- and macrovascular complications
C. Koulis et al.
DIABETES & METABOLISM (2015)
Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease
Sho-ichi Yamagishi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
DNA Aptamer Raised against Advanced Glycation End Products Prevents Abnormalities in Electroretinograms of Experimental Diabetic Retinopathy
Satoshi Maeda et al.
OPHTHALMIC RESEARCH (2015)
Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Cancer Risk
Sho-ichi Yamagishi et al.
REJUVENATION RESEARCH (2015)
Role of receptor for advanced glycation end products (RAGE) in liver disease
Sho-ichi Yamagishi et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2015)
DNA aptamer raised against advanced glycation end products inhibits neointimal hyperplasia in balloon-injured rat carotid arteries
Ayako Ojima et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice
Ayako Ojima et al.
LABORATORY INVESTIGATION (2014)
DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy
Yusuke Kaida et al.
DIABETES (2013)
Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review
N. J. Kellow et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2013)
Advanced glycation endproducts in food and their effects on health
Malene W. Poulsen et al.
FOOD AND CHEMICAL TOXICOLOGY (2013)
Review of the Characteristics of Food-Derived and Endogenous Nε-Carboxymethyllysine
Lipeng Han et al.
JOURNAL OF FOOD PROTECTION (2013)
Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells
Yuichiro Higashimoto et al.
MICROVASCULAR RESEARCH (2013)
Potential Clinical Utility of Advanced Glycation End Product Cross-Link Breakers in Age- and Diabetes-Associated Disorders
Sho-ichi Yamagishi
REJUVENATION RESEARCH (2012)
The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome
John Paul Vavalle et al.
FUTURE CARDIOLOGY (2012)
Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
Sho-ichi Yamagishi
CURRENT DRUG TARGETS (2011)
Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes
Sho-ichi Yamagishi
EXPERIMENTAL GERONTOLOGY (2011)
Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property
Sayaka Maeda et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2011)
AGE restriction in diabetes mellitus: a paradigm shift
Helen Vlassara et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy A Randomized Trial
Hugh S. Markus et al.
STROKE (2011)
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura
Petra Jilma-Stohlawetz et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)
Sho-ichi Yamagishi et al.
CURRENT DRUG TARGETS (2010)
Aptamers as therapeutics
Anthony D. Keefe et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice
Hiroyuki Unoki-Kubota et al.
PROTEIN AND PEPTIDE LETTERS (2010)
Dietary Advanced Glycation End Products and Aging
Claudia Luevano-Contreras et al.
NUTRIENTS (2010)
Cancer Malignancy Is Enhanced by Glyceraldehyde-Derived Advanced Glycation End-Products
Jun-Ichi Takino et al.
JOURNAL OF ONCOLOGY (2010)
Advanced glycation end products and insulin resistance
Hiroyuki Unoki et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease
Masayoshi Takeuchi et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
Aino Soro-Paavonen et al.
DIABETES (2008)
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications
Sho-ichi Yamagishi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes
Yuichiro Higashimoto et al.
MICROVASCULAR RESEARCH (2007)
Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation
Kazuo Nakamura et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes
Hiroyuki Unoki et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Prospective study of hyperglycemia and cancer risk
Par Stattin et al.
DIABETES CARE (2007)
Detection and determination of glyceraldehyde-derived pyridinium-type advanced glycation end product in streptozotocin-induced diabetic rats
Teruyuki Usui et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2007)
Food-derived advanced glycation end products (AGEs): A novel therapeutic target for various disorders
Sho-ichi Yamagishi et al.
CURRENT PHARMACEUTICAL DESIGN (2007)
Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy
Erica L. Fletcher et al.
CURRENT PHARMACEUTICAL DESIGN (2007)
Novel inhibitors of glycation and AGE formation
Samuel Rahbar
CELL BIOCHEMISTRY AND BIOPHYSICS (2007)
AGE, RAGE, and ROS in diabetic nephropathy
Adeline L. Y. Ton et al.
SEMINARS IN NEPHROLOGY (2007)
Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy
Michael Famulok et al.
CHEMICAL REVIEWS (2007)
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression
Sho-ichi Yamagishi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer
L Vicioso et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
The RAGE axis in early diabetic retinopathy
GR Barile et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
PDGF receptor kinase inhibitors for the treatment of restenosis
A Levitzki
CARDIOVASCULAR RESEARCH (2005)
Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy
S Yamagishi et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions
R Abe et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling
S Yamagishi et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding
G Sorci et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation
HJ Huttunen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy
MR Bennett et al.
PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
